Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lenvatinib is an oral kinase inhibitor and the active ingredient in Lenvima. Current U.S. labeling includes selected differentiated thyroid cancer, renal cell carcinoma, unresectable hepatocellular carcinoma, and advanced endometrial carcinoma under disease-specific criteria.
read more about lenvatinib ...Lenvatinib inhibits several receptor tyrosine kinases involved in tumor growth and formation of blood vessels, including vascular endothelial growth factor receptors, fibroblast growth factor receptors, RET, KIT, and platelet-derived growth factor receptor alpha.
Lenvatinib is used alone for radioactive iodine-refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma. It is used with pembrolizumab for first-line advanced renal cell carcinoma and selected advanced endometrial carcinoma, and with everolimus for advanced renal cell carcinoma after prior anti-angiogenic therapy.
Dosing depends on the cancer. Differentiated thyroid cancer uses 24 mg once daily. First-line advanced renal cell carcinoma uses 20 mg once daily with pembrolizumab, while previously treated renal cell carcinoma uses 18 mg once daily with everolimus. Unresectable hepatocellular carcinoma uses 12 mg daily at body weight of at least 60 kg and 8 mg daily below 60 kg. Advanced endometrial carcinoma uses 20 mg once daily with pembrolizumab.
Serious concerns include hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, kidney failure, proteinuria, severe diarrhea, gastrointestinal perforation or fistula, QT prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhage, thyroid dysfunction, impaired wound healing, osteonecrosis of the jaw, and fetal harm.
Current U.S. labeling includes selected thyroid, kidney, liver, and endometrial cancers.
The recommended dose is 24 mg once daily.
Yes. Recommended daily doses and combination medicines differ by cancer and prior treatment.
Yes. Lenvima contains lenvatinib.
DailyMed - LENVIMA (lenvatinib) capsule and kit. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4bedd21-efde-44c6-9d9c-b48b78d7ed1e. Date Accessed October 8, 2026.
Lenvatinib. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a615015.html. Date Accessed October 8, 2026.
Lenvatinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lenvatinib. Date Accessed October 8, 2026.
Lenvatinib Mesylate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/lenvatinibmesylate. Date Accessed October 8, 2026.
LENVIMA (lenvatinib) Prescribing Information. Eisai. https://www.lenvima.com/-/media/Project/EISAI/Lenvima/PDF/prescribing-information.pdf. Date Accessed October 8, 2026.